Considerations for the Development of Personalised Neoantigen-Based Cancer Vaccines

Time: 9:00 am
day: Day One


• Reviewing updates on current individualised cancer vaccine clinical approaches, successes, and challenges
• Considering factors for process design and specifications for a personalised neoantigen-based vaccine and a customised neoantigen based cell therapy
• Exploring approaches for dealing with human and process variability